Mostrando 2 resultados de: 2
Manufacturing process development for an epidermal growth factor-based cancer vaccine
ArticleAbstract: The Center for Molecular Immunology (Havana, Cuba) has been working on a novel cancer immunotherapyPalabras claves:Autores:Albisa A., Calvo L., Chico E., Cuevas A., Garcia A.T., García Verdecia B., González G., Portillo A., Rodríguez G., Tania Crombet, Viña L.Fuentes:scopusSystemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab
ArticleAbstract: Nimotuzumab (h-R3) is a humanized anti-epidermal growth factor receptor monoclonal antibody (mAb) rePalabras claves:animal model, CETUXIMAB, Epidermal growth factor receptor, General toxicity, H-R3, Monkeys, nimotuzumab, Skin toxicityAutores:Arteaga M.E., Ballester-Labrada A., Baro F., Boleda M., Casacó Parada A.R., Charro L., Fuentes D., García M., González B., González C., Hernández O., Ledón N., Macías A.E., Morales Y., Orphee R., Pardo B., Pérez A., Ramos M., Rodríguez V., Rodriquez L., Subirós N., Tania Crombet, Viña L.Fuentes:scopus